Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

BACKGROUND: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. AIMS: To compare differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajlan, Aziza, Aleid, Hassan, Ali, Tariq Zulfiquar, Joharji, Hala, Almeshari, Khalid, Nazmi, Ahmed Mohammed, Shah, Yaser, Devol, Edward, Alkortas, Dalal, Alabdulkarim, Zinah, Broering, Dieter, Alahmadi, Ibrahim, Ullah, Asad, Alotaibi, Anwar, Aljedai, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223264/
https://www.ncbi.nlm.nih.gov/pubmed/34167567
http://dx.doi.org/10.1186/s13063-021-05253-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223264/
https://www.ncbi.nlm.nih.gov/pubmed/34167567
http://dx.doi.org/10.1186/s13063-021-05253-1

Ejemplares similares